鴻富瀚(301086.SZ):子公司鴻富瀚軟件擬出資1875萬元參設合資公司
格隆匯11月26日丨鴻富瀚(301086.SZ)公佈,公司全資子公司深圳市鴻富瀚軟件技術有限公司(“鴻富瀚軟件”)於2021年11月24日與深圳市袍澤科技合夥企業(有限合夥)(“袍澤科技”)、無錫勝鋭斯新能源科技有限公司(“勝鋭斯新能源”)簽署《合作框架協議》,三方共同出資2500萬元在廣東省深圳市設立合資公司,其中鴻富瀚軟件認繳註冊資本1875萬元,佔註冊資本的75%,袍澤科技認繳註冊資本500萬元,佔註冊資本的20%,勝鋭斯新能源認繳註冊資本125萬元,佔註冊資本的5%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.